Combined Treatment for Recurrent Herpetic Stromal Keratitis with Ulceration: a Case Report


Herpes simplex keratitis (HSK) is a severe ophthalmic pathology which comprises 20-50% of inflammatory diseases in the cornea. Since keratitis is characterized by a long-term duration, severity, and a tendency to recurrence, studies on ophthalmic herpes and searches for new treatments are of great relevance.

Our clinical case demonstrated successful combined treatment of a recurrent stromal herpetic corneal lesion with ulceration. Both treatments, conservative (complex etiotropic, anti-viral, anti-inflammatory, and nutrition-improving) and surgical (onlay technique), were successful. At 12 months after surgery, the patient had no pain syndrome; the cornea was epithelialized. No recurrence of herpetic keratitis was observed. Thus, a combination of etiotropic pathogenic treatment and AM transplantation appears to be effective for severe long-lasting recurrent herpetic keratitis with the presence of defects on the corneal surface.
of corneal ulceration and complicated by pain syndrome (Fig. 3).

The microbiological testing of the conjunctiva discharge revealed staphylococcus epidermidis with a concentration of $< 10^7$.

Despite the etiotropic anti-viral and anti-inflammatory treatment, the patient’s condition improved insufficiently within 14 days. The corneal surface still had defects and active vascularization was noted in the periphery (Fig. 4).

The patient was recommended a curative operation, transplantation of cryopreserved amniotic membrane using an overlay technique with AM sutured to episclera and conjunctival surface reconstruction, which was performed on July 27, 2017. After surgery, the corneal surface with AM was covered with a bandage therapeutic soft contact lens (Fig. 5).

At Day 2, post-operatively, pain syndrome was managed; the patient continued the conservative etiotropic and anti-inflammatory treatment.

At 1.5 Months after amniotic membrane transplantation (AMT), the amnion was partially resorbed on the corneal surface. Corneal epithelization was complete and the fluorescein test was negative. Visual acuity improved to 0.3 (Fig. 6).

At 3 months after AMT, the complete resorption of the amnion and complete corneal epithelization were noted; the fluorescein test was negative. The vessels on the corneal surface were partially emptied. The Schirmer test and the Norn’s test increased to 10.0 mm to 12 s, respectively. Visual acuity improved to 0.5 (Fig. 7).

Within 5 postoperative months, the patient underwent the system anti-viral and anti-inflammatory treatment and local instillations of antiseptics, recombinant human interferon, dexamethasone, vitamins, and preservative-free tear-substitute with trehalose. The immunology testing showed: improved immune reactivity of the body; increased to the normal ranges pulse blood volume (RQ); tonic properties of the small vessels decreased by 20%; blood flow velocity increased by 30%. Visual acuity was 0.5.

Corneal epithelization, regressed vascularization, and decreased area of corneal opacity were noted at 12 months after AMT and a course of etiotropic anti-viral treatment. Visual acuity improved to 0.6 (Fig. 8).

At present, the patient is receiving tear-substitute treatment (preservative-free agents with trehalose), which improves corneal nutrition. Uncorrected visual acuity is 0.6.

**Discussion**

At the present time, treatment of herpetic ocular infection is a challenging task in ophthalmology. For treating herpetic diseases, there are numerous drugs which have etiotropic and immunocorrecting action depending on the etiology, pathology, and clinical symptoms. Antitherpetic drugs can be divided into three groups based on the mechanism of action: a chemotherapeutic agent, specific immune correctors, and non-specific immune correctors [2-6].

Antitherpetic drugs, which are used in ophthalmology as gel and ointment, are presented by acyclovir, an analogue of purine nucleoside blocking the viral DNA synthesis, and ganciclovir, a nucleoside and an analogue of guanine.

One of the leading roles in the complex antiviral therapy belongs to new-generation interferon-inducing drugs (tilorone, oxohydroacridinylacetate sodium, acridonacetic acid) which successfully combine etiotropic and immunocorrecting effects. The drugs induce the production of endogenous interferon by T and B lymphocytes, enterocytes, and hepatocytes [7].

Today, immune therapy for ophthalmic herpes includes specific (herpetic vaccine and herpetic immunoglobulin) and non-specific (interferons and interferon inducers, cytokines, micro-element vitamin complex, etc) methods. In addition, tear substitute drugs are used with the preference of preservative-free ones [8, 9]. To achieve the positive result of therapy, the duration of the complex antiviral therapy should be at least 4-6 months.

All the drug groups above were used in the complex treatment for the patient described.

The recurrence of herpetic keratitis and the formation of a long-lasting corneal defect require surgical treatment [10]. We draw our attention to amniotic membrane transplantation (AMT), one of the important recent techniques in ocular surface surgery [11].

Although AM was first performed in ophthalmology over 70 years ago, this is 1995 since when AMT has been widely used in patients and has shown good results [12]. Curative keratoplasty using an amnion or other long-term storage plastic materials has come into widespread acceptance [13-14].

The major indications to AMT for the reconstruction of the ocular surface are persistent corneal epithelial defects with ulceration of different etiology [15, 16].

Clinical studies have shown that AMT benefits epithelialization and differentiation of the ocular surface epithelium [15-18]. The most important growth factors for ocular surface wound healing, which are epidermal growth factor and keratinocyte growth factor, were mainly expressed in the amniotic epithelium but also in the stroma [17, 18].

There are several surgical AMT techniques. We used an onlay or patch technique. Classical indications for this technique vary from acute burn injuries to acute herpetic keratitis and severe Stevens-Johnson syndrome [14, 18, 19, 20]. This allows using wound healing and anti-inflammatory AM properties which are limited in time [18, 22].

In an onlay technique, a big portion of AM is placed on the ocular surface as a biological covering and sutured in the limbus or in the episclera [15].

In the case reported, AM successfully performed its anti-inflammatory and wound healing actions and was partially resorbed at 1.5 months. At 3 months after surgery,
AM was completely resorbed, which was accompanied by corneal epithelium healing. In addition, new vessels were partially emptied.

To conclude, the clinical case reported demonstrated successful combined treatment of a recurrent stromal herpetic corneal lesion with ulceration. A success was both complex conservative etiotropic, anti-viral, anti-inflammatory, and nutrition-improving treatment and surgical treatment using an onlay technique. At 12 months after surgery, the patients had no pain syndrome; the corneal surface was epithelialized. No recurrence of herpetic keratitis was observed.

Thus, a combination of etiotropic pathogenic treatment and AM transplantation appears to be effective for severe long-lasting recurrent herpetic keratitis with the presence of defects on the corneal surface.

References
Fig. 1. Corneal opacity and corneal vascularization, stromal swelling and corneal erosions are seen. Fig. 2. Condition after complex conservative treatment. Uneven vascularized corneal opacity. Fig. 3. Vascularized corneal opacity and corneal ulceration. Uncorrected visual acuity – 0.1 Fig. 4. Condition after complex conservative treatment. Vascularized corneal opacity. Corneal ulceration. Fig. 5. Condition after amniotic membrane transplantation. The cornea is completely covered with an amnion. The corneal surface is covered with a bandage therapeutic soft contact lens. Fig. 6. 1.5 months after AMT. Remnants of the amniotic membrane can be seen on the corneal surface. The cornea is opaque in the periphery. Fig. 7. 3 months after AMT. We can see paracentral opacity of the cornea with partially emptied new vessels. Fig. 8. 12 months after AMT. Paracentral corneal opacity.